Assessment of Detectable Serum Tobramycin Concentrations in Patients Receiving Inhaled Tobramycin for Ventilator-Associated Pneumonia

References

1. 1.↵
   1. Magill SS,
   2. Edwards JR,
   3. Bamberg W,
   4. Beldavs ZG,
   5. Dumyati G,
   6. Kainer MA,
   7. et al

   ; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care–associated infection. N Engl J Med 2014;370(13):1198-1208.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.
   1. Bouadma L,
   2. Sonneville R,
   3. Garrouste-Orgeas M,
   4. Darmon M,
   5. Souweine B,
   6. Voiriot G,
   7. et al

   . Ventilator-associated events: prevalence, outcome, and relationship with ventilator-associated pneumonia. Crit Care Med 2015;43(9):1798-1806.

   OpenUrlCrossRefPubMed
3. 3.
   1. Rello J,
   2. Ollendorf DA,
   3. Oster G,
   4. Vera-Llonch M,
   5. Bellm L,
   6. Redman R,
   7. et al

   . Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122(6):2115-2121.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Melsen WG,
   2. Rovers MM,
   3. Groenwold RH,
   4. Bergmans DC,
   5. Camus C,
   6. Bauer TT,
   7. et al

   . Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomized prevention studies. Lancet Infect Dis 2013;13(8):665-671.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Schreiber MP,
   2. Shorr AF

   . Inhaled antibiotics for the treatment of pneumonia. Curr Opin Pulm Med 2019 May;25(3):289-293.

   OpenUrl
6. 6.↵
   1. Ehrman S,
   2. Roche-Campo F,
   3. Bodet-Contentin L,
   4. Razazi K,
   5. Dugernier J,
   6. Trenado-Alvarez J,
   7. et al

   ; Reva Research Network. Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med 2016;42(2):192-201.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Kalil AC,
   2. Metersky ML,
   3. Klompas M,
   4. Muscedere J,
   5. Sweeney DA,
   6. Palmer LB,
   7. et al

   . Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63(5):e61-e111. Epub 2016 July 14. Erratum in: Clin Infect Dis 2017;64(9):1298. Erratum in: Clin Infect Dis 2017;65(8):1435. Erratum in: Clin Infect Dis 2017;65(12):2161.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Le J,
   2. Ashley ED,
   3. Neuhauser MM,
   4. Brown J,
   5. Gentry C,
   6. Klepser ME,
   7. et al.

   Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Pharmacotherapy 2010;30(6):562-584.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Wood GC,
   2. Swanson JM

   . An update on aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia in adults. Ann Pharmacother 2017;51(12):1112-1121.

   OpenUrl
10. 10.↵
    1. Le Conte P,
    2. Potel G,
    3. Peltier P,
    4. Horeau D,
    5. Caillon J,
    6. Juvin ME,
    7. et al

    . Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993;147(5):1279-1282.

    OpenUrlPubMedWeb of Science
11. 11.
    1. Geller DE,
    2. Pitlick WH,
    3. Nardella PA,
    4. Tracewell WG,
    5. Ramsey BW

    . Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-226.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.
    1. Badia JR,
    2. Soy D,
    3. Adrover M,
    4. Ferrer M,
    5. Sarasa M,
    6. Alarcón A,
    7. et al

    . Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004;54(2):508-514.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Kahler DA,
    2. Schowengerdt KO,
    3. Fricker FJ,
    4. Mansfield M,
    5. Visner GA,
    6. Faro A,
    7. et al

    . Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003;23(4):543-545.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Restrepo MI,
    2. Keyt H,
    3. Reyes LF

    . Aerosolized antibiotics. Respir Care 2015;60(6):762-773.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Cannella CA,
    2. Wilkinson ST

    . Acute renal failure associated with inhaled tobramycin. Am J Health Syst Pharm 2006;63(19):1858-1861.

    OpenUrlAbstract/FREE Full Text
16. 16.
    1. Langley A,
    2. Cottingham L

    . Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation. Am J Health Syst Pharm 2011;68(15):1385-1386.

    OpenUrlFREE Full Text
17. 17.
    1. Izquierdo MJ,
    2. Gomez-Alamillo C,
    3. Ortiz F,
    4. Calabia ER,
    5. Ruiz JC,
    6. de Francisco AL,
    7. Arias M

    . Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol 2006;66(6):464-467.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Hoffmann IM,
    2. Rubin BK,
    3. Iskandar SS,
    4. Schechter MS,
    5. Nagaraj SK,
    6. Bitzan MM

    . Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34(5):375-377.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Edson RS,
    2. Brey RH,
    3. McDonald TJ,
    4. Terrell CL,
    5. McCarthy JT,
    6. Thibert JM

    . Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79(9):1185-1191.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Zhang C,
    2. Berra L,
    3. Klompas M

    . Should aerosolized antibiotics be used to treat ventilator-associated pneumonia? Respir Care 2016;61(6):737-748.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2(1):1-138.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Vincent JL,
    2. Moreno R,
    3. Takala J,
    4. Willatts S,
    5. De Mendonça A,
    6. Bruining H,
    7. et al

    . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22(7):707-710.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Miller JL,
    2. Lepa TM,
    3. Ranallo C,
    4. Chaaban H,
    5. Skrepnek GH,
    6. Johnson PN

    . Detectable concentrations of inhaled tobramycin in critically ill children without cystic fibrosis: should routine monitoring be recommended? Pediatr Crit Care Med 2017;18(12):e615-e620.

    OpenUrl
24. 24.↵
    1. de Velde F,
    2. Emonts M,
    3. Verbruggen S,
    4. van der Sijs H

    . High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure. J Antimicrob Chemother 2014;69(11):3163-3164.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Miller T,
    2. Pastuch C,
    3. Garavaglia L,
    4. Gannon K,
    5. Parravani A

    . Unknown renal impairment: a rare case of inhaled tobramycin-induced acute kidney injury in a cystic fibrosis patient. Antibiotics (Basel) 2021;10(4):424.

    OpenUrl
26. 26.
    1. Ahya VN,
    2. Doyle AM,
    3. Mendez JD,
    4. Lipson DA,
    5. Christie JD,
    6. Blumberg EA,
    7. et al

    . Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24(7):932-935.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Kaufman AC,
    2. Eliades SJ

    . Vestibulotoxicity in a patient without renal failure after inhaled tobramycin. Am J Otolaryngol 2019;40(3):456-458.

    OpenUrl
28. 28.↵
    1. Luyt CE,
    2. Eldon MA,
    3. Stass H,
    4. Gribben D,
    5. Corkery K,
    6. Chastre J

    . Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with Gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv 2011;24(4):183-190.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Clay MM,
    2. Pavia D,
    3. Newman SP,
    4. Clarke SW

    . Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 1983;38(10):755-759.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Sakagami M

    . In vivo, in vitro, and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58(9-10):1030-1060.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Lopez-Novoa JM,
    2. Quiros Y,
    3. Vicente L,
    4. Morales AI,
    5. Lopez-Hernandez FJ

    . New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79(1):33-45.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.
    1. Rybak MJ,
    2. Abate BJ,
    3. Kang SL,
    4. Ruffing MJ,
    5. Lerner SA,
    6. Drusano GL

    . Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43(7):1549-1555.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Murry KR,
    2. McKinnon KR,
    3. Mitrzyk B,
    4. Rybak MJ

    . Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999;19(11):1252-1260.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Trongtrakul K,
    2. Patumanond J,
    3. Kongsayreepong S,
    4. Morakul S,
    5. Pipanmekaporn T,
    6. Akaraborworn O,
    7. Poopipatpab S

    . Acute kidney injury risk prediction score for critically ill surgical patients. BMC Anesthesiol 2020;20(1):140.

    OpenUrlPubMed
35. 35.↵
    1. Mou Z,
    2. Guan T,
    3. Chen L

    . Risk factors of acute kidney injury in ECMO patients: a systematic review and meta-analysis. J Intensive Care Med 2021:088506662110034. [Epub ahead of print].